Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.
Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.
Prolia® (denosumab), the first and only approved RANK Ligand inhibitor, has filed for approval worldwide for the treatment of postmenopausal osteoporosis.
FORTEO [teriparatide (rDNA origin) injection] can be used to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis, and for patients with osteoporosis associated with sustained glucocorticoi